Evaluation of the relationship between infiltrating lymphocytes and inflammatory response in breast cancer: A systematic review
DOI:
https://doi.org/10.33448/rsd-v12i14.44503Keywords:
Breast neoplasms; Tumor infiltrating lymphocytes; Inflammation.Abstract
Breast cancer is the most incident type of cancer in women worldwide and delays in its diagnosis and treatment potentially reduce survival rates. It is a heterogeneous disease and rich in stromal and inflammatory immune cells and soluble factors in its tumor microenvironment. Tumor infiltrating lymphocytes (TILs) are components of this inflammatory microenvironment and the density of TILs has proved to be an important tool in mediating the effectiveness of immunomodulatory therapies and in the prognosis of residual disease after neoadjuvant chemotherapy treatment. The aim of this study was to evaluate the relation between infiltrating lymphocytes and the inflammatory response in women with breast cancer. This is a descriptive, qualitative, systematic literature review study. The databases used to search for articles were Pubmed, Scielo and Cochrane, using the keywords “infiltrating lymphocytes, inflammatory response and breast cancer”, and the Boolean operator “And”. Complete articles published between 2012 and 2022 in English, Portuguese and Spanish, were included. The review was performed according to the PRISMA recommendation (Key Items for Reporting Systematic Reviews and Meta-analysis) and the Joana Briggs Institute (JBI) Appraisal Tools to assess the risk of selected studies. 91 articles were found, of which 17 were selected to be part of this review. The reviewed studies reveal a strong correlation between tumor stromal infiltrating lymphocytes (TILs) and tumor immune response, which may become an important measure for detecting the prognosis and survival of the disease.
References
Arias-Pulido, H., Cimino-Mathews, A., Chaher, N., Qualls, C., Joste, N., Colpaert, C., Marotti, J. D., Foisey, M., Prossnitz, E. R., Emens, L. A., & Fiering, S. (2018). The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. Breast Cancer Research and Treatment, 171(2), 273–282. https://doi.org/10.1007/s10549-018-4834-7
Badiu, D. C., Zgura, A., Gales, L., Iliescu, L., Anghel, R., & Haineala, B. (2021). Modulation of immune system—Strategy in the treatment of breast cancer. In Vivo (Athens, Greece), 35(5), 2889–2894. https://doi.org/10.21873/invivo.12578
Berben, L., Floris, G., Kenis, C., Dalmasso, B., Smeets, A., Vos, H., Neven, P., Antoranz Martinez, A., Laenen, A., Wildiers, H., & Hatse, S. (2020). Age-related remodelling of the blood immunological portrait and the local tumor immune response in patients with luminal breast cancer. Clinical & Translational Immunology, 9(10), e1184. https://doi.org/10.1002/cti2.1184
Bravo, B. S., Lopes, A. B. B., Tijolin, M. B., Nunes, P. L. P., Lenhani, T., Junior, S. F. D., & Ceranto, D. D. C. F. B. (2021). Câncer de mama: Uma revisão de literatura/ Breast cancer: a literature review. Brazilian Journal of Health Review, 4(3), 14254–14264. https://doi.org/10.34119/bjhrv4n3-357
Campedel, L., Blanc-Durand, P., Bin Asker, A., Lehmann-Che, J., Cuvier, C., De Bazelaire, C., Teixeira, L., Becourt, S., Ledoux, F., Hocini, H., Bourstyn, E., Miquel, C., Guillerm, S., Charveriat, P., Espié, M., De Roquancourt, A., Hamy, A.-S., & Giacchetti, S. (2020). Prognostic impact of stromal immune infiltration before and after neoadjuvant chemotherapy (Nac) in triple negative inflammatory breast cancers (Tnibc) treated with dose-dense dose-intense nac. Cancers, 12(9), 2657. https://doi.org/10.3390/cancers12092657
Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.1 [updated June 2000]. In: Review Manager (RevMan) [Computer program]. Version 4.1. Oxford, England: The Cochrane Collaboration, 2000. Available from: http://www.cochrane.dk/ cochrane/handbook/hanbook.htm
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., Von Törne, C., Weichert, W., Engels, K., Solbach, C., Schrader, I., Dietel, M., & Von Minckwitz, G. (2010). Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. Journal of Clinical Oncology, 28(1), 105–113. https://doi.org/10.1200/JCO.2009.23.7370
Dong, X., Liu, C., Yuan, J., Wang, S., Ding, N., Li, Y., Wu, Y., & Xiao, Z. (2021). Prognostic roles of neutrophil-to-lymphocyte ratio and stromal tumor-infiltrating lymphocytes and their relationship in locally advanced triple-negative breast cancer treated with neoadjuvant chemotherapy. Breast Care (Basel, Switzerland), 16(4), 328–334. https://doi.org/10.1159/000509498
Fernandez, S. V., MacFarlane, A. W., Jillab, M., Arisi, M. F., Yearley, J., Annamalai, L., Gong, Y., Cai, K. Q., Alpaugh, R. K., Cristofanilli, M., & Campbell, K. S. (2020). Immune phenotype of patients with stage IV metastatic inflammatory breast cancer. Breast Cancer Research: BCR, 22(1), 134. https://doi.org/10.1186/s13058-020-01371-x
Fragomeni, S. M., Sciallis, A., & Jeruss, J. S. (2018). Molecular subtypes and local-regional control of breast cancer. Surgical Oncology Clinics of North America, 27(1), 95–120. https://doi.org/10.1016/j.soc.2017.08.005
Galvão, T. F., Pansani, T, & Harrad, D. (2015). Principais itens para relatar Revisões sistemáticas e Meta-análises: A recomendação PRISMA. Epidemiologia e Serviços de Saúde [online], 24(2), 335-342. https://doi.org/10.5123/S1679-49742015000200017.
Gomes, I. S. & Caminha, I. O. (2014). Guia para estudos de revisão sistemática: uma opção metodológica para as Ciências do Movimento Humano. Movimento. 20 (1), 395-411.
Instituto Nacional De Câncer - Inca. (2023). Normas e recomendações do instituto nacional de câncer/ms. Revista Brasileira de Cancerologia, 46(1), 23–33. https://doi.org/10.32635/2176-9745.RBC.2000v46n1.3398
Korlimarla, A., Ps, H., Prabhu, J., Ragulan, C., Patil, Y., Vp, S., Desai, K., Mathews, A., Appachu, S., Diwakar, R. B., Bs, S., Melcher, A., Cheang, M., & Sadanandam, A. (2022). Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers. Translational Oncology, 25, 101511. https://doi.org/10.1016/j.tranon.2022.101511
Li, X., Warren, S., Pelekanou, V., Wali, V., Cesano, A., Liu, M., Danaher, P., Elliott, N., Nahleh, Z. A., Hayes, D. F., Hortobagyi, G. N., Barlow, W. E., Hatzis, C., & Pusztai, L. (2019). Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial. Journal for Immunotherapy of Cancer, 7(1), 88. https://doi.org/10.1186/s40425-019-0563-7
Lusho, S., Durando, X., Mouret-Reynier, M.-A., Kossai, M., Lacrampe, N., Molnar, I., Penault-Llorca, F., Radosevic-Robin, N., & Abrial, C. (2021). Platelet-to-lymphocyte ratio is associated with favorable response to neoadjuvant chemotherapy in triple negative breast cancer: A study on 120 patients. Frontiers in Oncology, 11, 678315. https://doi.org/10.3389/fonc.2021.678315
Miskad, U. A., Rifai, R. A., Masadah, R., Nelwan, B., Ahmad, D., Cangara, H., Prihantono, P., Zainuddin, A. A., & Rahawarin, H. (2021). The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type. Breast Disease, 40(s1), S9–S14. https://doi.org/10.3233/BD-219002
Mohammed, Z. M. A., Going, J. J., Edwards, J., Elsberger, B., Doughty, J. C., & McMillan, D. C. (2012). The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. British Journal of Cancer, 107(5), 864–873. https://doi.org/10.1038/bjc.2012.347
Oshi, M., Newman, S., Tokumaru, Y., Yan, L., Matsuyama, R., Endo, I., & Takabe, K. (2020). Inflammation is associated with worse outcome in the whole cohort but with better outcome in triple-negative subtype of breast cancer patients. Journal of Immunology Research, 2020, 5618786. https://doi.org/10.1155/2020/5618786
Park, Y. H., Lal, S., Lee, J. E., Choi, Y.-L., Wen, J., Ram, S., Ding, Y., Lee, S.-H., Powell, E., Lee, S. K., Yu, J. H., Ching, K. A., Nam, J.-Y., Kim, S. W., Nam, S. J., Kim, J.-Y., Cho, S. Y., Park, S., Kim, J., … Kan, Z. (2020). Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nature Communications, 11(1), 6175. https://doi.org/10.1038/s41467-020-19933-0
Pavel, D., Nemejcová, K., Bártů, M., Matěj, R., Rohan, Z., & Tichá, I. (2017). Evaluation of inflammatory cells (Tumor infiltrating lymphocytes) in solid tumors. Klinicka Onkologie, 30(Suppl 3), 3S10-3S21. https://doi.org/10.14735/amko20173S10
Rother, E. T. (2007). Revisão sistemática X revisão narrativa. Acta Paulista de Enfermagem, 20(2), v–vi. https://doi.org/10.1590/S0103-21002007000200001
Sartori, A. C. N., & Basso, Caroline S. (2019). Breast cancer: A brief review of the literature. Perspectiva, Erechim, 43(161), 07–13.
Van Berckelaer, C., Rypens, C., van Dam, P., Pouillon, L., Parizel, M., Schats, K. A., Kockx, M., Tjalma, W. a. A., Vermeulen, P., van Laere, S., Bertucci, F., Colpaert, C., & Dirix, L. (2019). Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. Breast Cancer Research: BCR, 21(1), 28. https://doi.org/10.1186/s13058-019-1108-1
Van Berckelaer, C., Van Geyt, M., Linders, S., Rypens, C., Trinh, X. B., Tjalma, W. a. A., Van Laere, S., Colpaert, C., Dirix, L., & van Dam, P. A. (2020). A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer. Breast (Edinburgh, Scotland), 53, 212–220. https://doi.org/10.1016/j.breast.2020.08.006
Van Berckelaer, C., Vermeiren, I., Vercauteren, L., Rypens, C., Oner, G., Trinh, X. B., Tjalma, W. A. A., Broeckx, G., Charafe-Jauffret, E., Van Laere, S., Bertucci, F., Colpaert, C., & van Dam, P. A. (2021). The evolution and prognostic role of tumour-infiltrating lymphocytes and peripheral blood-based biomarkers in inflammatory breast cancer patients treated with neoadjuvant chemotherapy. Cancers, 13(18), 4656. https://doi.org/10.3390/cancers13184656
Vihervuori, H., Autere, T. A., Repo, H., Kurki, S., Kallio, L., Lintunen, M. M., Talvinen, K., & Kronqvist, P. (2019). Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology, 145(12), 3105–3114. https://doi.org/10.1007/s00432-019-03036-5
Wang, T., Li, T., Li, B., Zhao, J., Li, Z., Sun, M., Li, Y., Zhao, Y., Zhao, S., He, W., Guo, X., Ge, R., Wang, L., Ding, D., Liu, S., Min, S., & Zhang, X. (2022). Immunogenomic landscape in breast cancer reveals immunotherapeutically relevant gene signatures. Frontiers in Immunology, 13, 805184. https://doi.org/10.3389/fimmu.2022.805184.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Jacqueline Moraes Gomes; Ester Araújo Esper; Andrea Alves Ribeiro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
